Do systemic corticosteroids worsen active fungal infections?

Systemic Corticosteroids Generally Worsen Active Fungal Infections

Systemic corticosteroids significantly worsen outcomes in most active fungal infections and should be avoided or minimized whenever possible, with rare exceptions limited to specific clinical scenarios where they may provide benefit alongside antifungal therapy. 1

Evidence of Harm Across Major Fungal Infections

The relationship between corticosteroids and fungal infections is predominantly harmful:

Invasive Aspergillosis and Chronic Pulmonary Aspergillosis

• Corticosteroids increase mortality risk by 2.5-fold in invasive aspergillosis (HR: 2.50) and 2.7-fold in chronic pulmonary aspergillosis (HR: 2.74). 1
• Doses exceeding 2 mg/kg/day of prednisone equivalents are particularly dangerous, increasing mortality risk nearly 3-fold (HR: 2.94). 1
• Corticosteroid use is a major risk factor for developing aspergillosis, especially in COVID-19 patients. 1

Invasive Candidiasis and Candidemia

• Corticosteroids more than double the risk of invasive candidiasis and candidemia (OR: 2.13). 1
• The risk with corticosteroids is substantially higher than with other immunosuppressive agents—corticosteroids carry 5.4-fold increased risk compared to 1.6-fold with anti-TNF agents. 2
• Corticosteroids are recognized as a primary risk factor for breakthrough fungal infections in immunocompromised hosts. 3

Mucormycosis

• Corticosteroids increase mucormycosis risk over 4-fold (OR: 4.19). 1
• This represents one of the strongest associations between steroid use and fungal infection worsening. 1

Pneumocystis jirovecii Pneumonia (PCP)

• In non-HIV patients with PCP, corticosteroids worsen outcomes (OR: 1.29). 1
• This contrasts sharply with HIV-infected PCP patients, where corticosteroids actually improve survival (RR: 0.62). 1

Fungal Keratitis

• Early corticosteroid use in fungal keratitis worsens visual outcomes 3-fold (OR: 2.99). 1

Mechanism of Harm

Corticosteroids create vulnerability through complex immune dysregulation:

• They profoundly impair cell-mediated immunity, which is critical for controlling fungal pathogens. 4
• The immunosuppressive effects are dose-dependent and cumulative. 4
• Corticosteroids contribute to the "net state of immunosuppression" that directly increases infection risk and severity. 3

Limited Exceptions Where Steroids May Be Considered

Chronic Disseminated Candidiasis (Hepatosplenic Candidiasis)

• Short-term corticosteroids (1-2 weeks) can be considered for debilitating persistent fevers in chronic disseminated candidiasis, but only when given alongside appropriate antifungal therapy. 5
• This represents a potential immune reconstitution syndrome where inflammation may be more problematic than the infection itself. 5
• Typical dosing is 0.5-1 mg/kg/day oral prednisone, tapered over several weeks. 5
• However, the role remains unclear and this is a weak recommendation. 5

Allergic Fungal Conditions

• Topical nasal steroids are recommended for allergic fungal rhinosinusitis to reduce symptoms and increase time to relapse, especially post-surgery. 6
• Oral corticosteroids may be used in asthmatic patients with allergic bronchopulmonary aspergillosis, though the goal is to minimize their use with antifungal therapy. 6

HIV-Associated PCP

• Corticosteroids improve survival in HIV-infected patients with PCP (RR: 0.62). 1

Post-Keratoplasty in Fungal Keratitis

• After keratoplasty surgery for fungal keratitis, corticosteroids may improve outcomes (OR: 0.01). 1

Clinical Approach

When managing patients with active fungal infections:

1. Discontinue or minimize corticosteroids immediately if clinically feasible. 1, 4
2. If corticosteroids cannot be stopped, reduce to the lowest effective dose, ideally below 2 mg/kg/day prednisone equivalents. 1
3. Initiate aggressive antifungal therapy before considering any corticosteroid use in the rare exceptions noted above. 5
4. Monitor closely for breakthrough infections in patients requiring ongoing corticosteroid therapy. 3

Critical Pitfalls to Avoid

• Do not assume dose-independent risk: Higher corticosteroid doses (>20 mg/day prednisone equivalent) carry substantially greater risk. 1
• Do not extrapolate HIV-PCP data to non-HIV patients: The benefit seen in HIV-associated PCP does not apply to other populations. 1
• Do not use corticosteroids early in fungal keratitis: This significantly worsens visual outcomes. 1
• Do not delay antifungal therapy when considering corticosteroids for immune reconstitution syndromes. 5

The evidence overwhelmingly demonstrates that corticosteroids worsen most fungal infections through profound immunosuppression, and minimizing their use is essential for improving outcomes in life-threatening and vision-threatening fungal diseases. 1, 4